The aim of this study was to evaluate whether the plasma levels of “endothelial” and “alveolar” biomarkers (Ang-2, ICAM-1, VCAM-1, P selectin, E-selectin and RAGE) vary over time between survivors and non-survivors in COVID-19-related ARDS patients. This evidence concerns the gene ICAM1 and acute respiratory distress syndrome.